Related Experiment Video
Updated: Mar 13, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
7.4K
Recent advances in neutralizing the IL-6 pathway in arthritis
1Division of Rheumatic Diseases, Case Western Reserve University, School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio, USA.
Open Access Rheumatology : Research and Reviews
|October 5, 2009
Summary
Interleukin-6 (IL-6) trans-signaling drives autoimmune arthritis inflammation. Tocilizumab, an IL-6 receptor inhibitor, shows clinical benefits in rheumatoid arthritis by reducing IL-6 levels and disease progression.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is a key cytokine implicated in the pathogenesis of various autoimmune and inflammatory conditions, including rheumatoid arthritis (RA).
- Elevated levels of IL-6 are observed in serum and synovial fluid across multiple arthritic diseases such as RA, psoriatic arthritis, ankylosing spondylitis, and osteoarthritis.
- IL-6 plays a crucial role in immune cell differentiation and function, particularly in T helper 17 (TH17) cell development and B-lymphocyte activity.
Approach:
- This review critically examines the mechanisms by which IL-6 trans-signaling contributes to immune cell dysregulation and inflammation in autoimmune arthritis.
- It discusses the development and clinical application of tocilizumab, a monoclonal antibody targeting the IL-6 receptor (IL-6R), as a therapeutic strategy.
- Clinical trial data demonstrating the efficacy of tocilizumab in treating RA patients are analyzed.
Key Points:
- IL-6 trans-signaling is a critical pathway in promoting inflammation in autoimmune arthritis.
- Tocilizumab has demonstrated significant clinical benefits in RA patients, including reduced disease activity and radiographic progression.
- IL-6 influences the differentiation of CD4+ lymphocytes into TH17 cells and modulates B-lymphocyte function.
Conclusions:
- Targeting IL-6 trans-signaling with tocilizumab represents a successful therapeutic strategy for rheumatoid arthritis.
- Further research is needed to ascertain whether IL-6 trans-signaling inhibition can impact other related cytokines elevated in RA.
- Understanding IL-6's role provides insights into immune regulation and potential therapeutic targets for inflammatory diseases.
Related Concept Videos
01:24T Cell Types and Functions
3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
01:20The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
01:28Inflammatory Response
18.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.0K
01:16TGF - β Signaling Pathway
10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631